OncoTherapy ScienceTSE:4564 +5.00%50 Median PS Value is 円111.37 as of Jul. 08, 2026, which is 100% below its 10-year median of 0.44. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.04 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 276 Biotechnology companies, OncoTherapy Science ranks better than 88.77% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for OncoTherapy Science's Median PS Value or its related term are showing as below:
TSE:4564'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13 Med: 0.44 Max: 11.76
Current: 0.19
During the past 13 years, the highest Price to Median PS Value of OncoTherapy Science was 11.76. The lowest was 0.13. And the median was 0.44.
TSE:4564's Price-to-Median-PS-Value is ranked better than 88.77% of 276
companies
in the Biotechnology industry
Industry Median: 0.65
vs TSE:4564: 0.19
OncoTherapy Science (TSE:4564) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
OncoTherapy Science's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
21.00
/
111.37
=
0.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science Median PS Value Related Terms
OncoTherapy Science Median PS Value Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, OncoTherapy Science's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 45.4571.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OncoTherapy Science's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円2.45.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (TSE:4564) has a Median PS Value of 円111.37 as of Jul. 08, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on OncoTherapy Science and its competitors. This is 25211% above median its historical median of 0.44. Over the past decade, OncoTherapy Science's Median PS Value has ranged from 0.13 to 11.76. According to the industry distribution chart, OncoTherapy Science ranks #31 out of 276 companies in the Biotechnology industry, placing it in the top 11.2%.
Is OncoTherapy Science's Median PS Value too high?
OncoTherapy Science's current Median PS Value of 円111.37 is 25211% above median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 11.76. Based on the distribution chart, OncoTherapy Science ranks #31 out of 276 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #31 out of 276 companies for Median PS Value. This places OncoTherapy Science in the top 11% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.65. Historically, OncoTherapy Science's own Median PS Value has ranged from 0.13 to 11.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current Median PS Value is 円111.37, which is 25211% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.04, compared to a current price of 円21.00 — trading 23.2% above its estimated fair value. The current Median PS Value is 円111.37, which is 25211% above median its 10-year median of 0.44. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Median PS Value is 円111.37 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円21.00 is trading 23.2% above its estimated GF Value™ of 円17.04.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Median PS Value: 円111.37 (25211% above median its 10-year median of 0.44)
GF Value™: 円17.04 vs. price of 円21.00 (23.2% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
